Recon: FDA misses PDUFA goal date for Agios' thalassemia therapy; Mirum to buy Bluejay for up to $820M
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States